Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.55 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.55 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.55 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | XDH | P47989 | 1/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 4/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | PNP | P00491 | 1/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.38 |
| ▸ | POLA1 | P09884 | 1/20 | 0.36 |
| ▸ | G6PD | P11413 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 3/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153896 | 0.74 | ALDH1A1 (0.41) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL2696766 | 0.74 | ALDH1A1 (0.41) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL5479715 | 0.74 | DPP4 (0.50) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL29077040 | 0.72 | PI4KA (0.92) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL29355156 | 0.71 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL29982697 | 0.71 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL3414606 | 0.71 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL29466915 | 0.71 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL1331751 | 0.71 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL8111 | 0.71 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119351-A1 | THERAPY OF TUMORS AND INFECTIOUS AGENTS DEFICIENT IN METHYLTHIOADENOSINE PHOSPHORYLASE | LUBIN ADAM (US) | 2015-04-30 | — | — | US | claimed |
| US-8796241-B2 | Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase | LUBIN ADAM (US) | 2014-08-05 | — | — | US | claimed |
| US-20120094947-A1 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2012-04-19 | — | — | US | claimed |
| EP-2192905-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | Lubin, Adam (US) | 2010-06-09 | — | — | EP | claimed |
| US-20090306360-A1 | 2-AZAPURINE COMPOUNDS AND THEIR USE | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2009-12-10 | — | — | US | claimed |
| WO-2009032057-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2009-03-12 | — | — | WO | claimed |
| US-20070015725-A1 | 2-azapurine compounds and their uses | ROCHE DIAGNOSTICS, GMBH (US) | 2007-01-18 | — | — | US | claimed |
| CN-1238519-C | Process for producing nucleoside compound | MITSUI CHEMICALS INC (JP) | 2006-01-25 | — | — | CN | claimed |
| EP-1214331-A2 | 2-AZAPURINE COMPOUNDS AND THEIR USE | Roche Diagnostics GmbH (DE) | 2002-06-19 | — | — | EP | claimed |
| WO-2001016149-A2 | 2-AZAPURINE COMPOUNDS AND THEIR USE | ROCHE DIAGNOSTICS GMBH (DE) | 2001-03-08 | — | — | WO | claimed |
| US-5478928-A | Useful as antiviral agents in the treatment and prevention of AIDS | SOUTHERN RESEARCH INSTITUTE (US) | 1995-12-26 | — | — | US | claimed |
| WO-1995011685-A1 | 2',3'-DIDEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1995-05-04 | — | — | WO | claimed |
| JP-11278977-A | — | — | None | — | — | JP | disclosed |
| WO-2026100734-A1 | PHOTOSENSITIVE RESIN COMPOSITION, CURED PRODUCT, PATTERNED CURED PRODUCT PRODUCTION METHOD, AND ELECTRONIC COMPONENT | ＨＤマイクロシステムズ株式会社 | 2026-05-15 | — | — | WO | disclosed |
| WO-2026100338-A1 | PHOTOSENSITIVE RESIN COMPOSITION AND METHOD FOR PRODUCING CURED RELIEF PATTERN | 旭化成株式会社 | 2026-05-15 | — | — | WO | disclosed |
| WO-2026100079-A1 | PHOTOSENSITIVE RESIN COMPOSITION, CURED PRODUCT, PATTERNED CURED PRODUCT PRODUCTION METHOD, AND ELECTRONIC COMPONENT | ＨＤマイクロシステムズ株式会社 | 2026-05-15 | — | — | WO | disclosed |
| EP-0525106-A1 | 2',3'-DIDEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1993-02-03 | — | — | EP | disclosed |
| US-5128458-A | 2',3'-dideoxy-4'-thioribonucleosides as antiviral agents | SOUTHERN RESEARCH INSTITUTE (US) | 1992-07-07 | — | — | US | disclosed |
| WO-1991016333-A1 | 2',3'-DIDEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1991-10-31 | — | — | WO | disclosed |
| US-3935184-A | Synthetic polyoxin type nucleosides | SYNTEX (U.S.A.) INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306360-A1 | 2-AZAPURINE COMPOUNDS AND THEIR USE | ADAR, AMPD2, NSUN2 | PI4KA 2034/4885PI4K2B 1565/4885PI4K2A 1244/4885 |
| US-20070015725-A1 | 2-azapurine compounds and their uses | ADAR, NSUN2, AMPD2 | PI4KA 2108/4885PI4K2B 1594/4885PI4K2A 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.